Negotiated settlement between Insmed Corporation and Tercica(and Tercica's associated licensing companies Genentech and Cephalon) has devastating impact on ALS Patients worldwide. Iplex, (an IGF-1 medication with an IGF-3 binding protein component), produced by Insmed, has been taken off the market. This drug, given by injection once daily, is the first to show benefit for ALS, HIV-Aids, Myotonic Muscular Dystrophy and burn victims. Because of a patent infringement, the settlement winner Tercica, is pulling all Iplex off the market and replacing it with their own inferior product, Increlex, which offers little or no benefit for these patients. Even at an astronomical cost to patients, ( $9500 a month) the demand is great, the supply unavailable. In fact, Tercica is recommending that all remaining supplies be destroyed rather than providing it to those in dire need. The bottom line is money over life-the obvious 21st century mantra for the pharmaceutical industry.
All,
There is no evidence yet published to suggest that Tercica's product Increlex will benefit any of these conditions: ALS, HIV-AIDS, severe burn, fractured hip, Myotonic Muscular Dystrophy.
PLEASE stop ignoring requests for Iplex, begin distribution immediately and continue to provide the Iplex product to the ALS and other communities who have already experienced positive affects.
Thank you,
50
50
log in or sign up to start earning Butterfly Credits today!
Keep up the great work. Look what you've accomplished!
1
0
0
0
grab this widget
for your site or blog
Make a difference for the issues you care about while adding cool interactive
content. Your readers sign without ever leaving your site. It's simple, just choose
your widget size and color and copy the embed code to your site or blog.